Myelodysplastic Syndrome with Excess Blasts

Myelodysplastic Syndrome with Excess Blasts — Trials · CancerIndex

Clinical trials

Registered studies

76 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 23
Recruiting: 12
Ph III recruiting: 0
Growth YoY: —
Industry share: 17%
Top sponsor: National Cancer Institute (NCI)
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (9)

clinicaltrialsPublishedShowing 1–5 of 5 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03779854	Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant	active not recruiting	Phase 2	45	Fred Hutchinson Cancer CenterOTHER	1	Sep 25, 2026	clinicaltrials
NCT01522976	Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia	active not recruiting	Phase 2	282	National Cancer Institute (NCI)NIH	2